Abstracts

CMV VACCINE VECTOR-INDUCED PROTECTION AGAINST SIV IN MAURITIAN CYNOMOLGUS MACAQUES

Strain 68-1 rhesus cytomegalovirus (CMV) vaccine vectors expressing simian immunodeficiency virus (SIV) antigens (RhCMV/SIV) prime broadly-targeted, unconventionally MHC-II- and MHC-E-restricted CD8+ T cell responses that stringently control SIV replication in vaccinated rhesus macaques (RM). However, RM express many more MHC-II and MHC-E alleles than humans, and it remains unclear if the unprecedented cellular immunity and…

HARNESSING ORIGINAL ANTIGENIC SIN FOR PREVENTING MTCT OF HIV

  Progress towards the elimination of pediatric HIV infection via mother to child transmission (MTCT) is limited by several factors, including inconsistent access and maternal adherence to ART. The development of a maternal vaccine that can synergize with current ART prophylaxis could overcome implementation challenges impeding achievement of an HIV-free generation. Both the epitope specificity of…

CD40-TARGETED VACCINE INCREASES MAGNITUDE OF HIV-ENV SPECIFIC RESPONSES

The development of DC-targeted vaccines aims to increase immunogenicity of proteins through improved delivery of the antigens to specific antigen-presenting cells playing a key role in inducing and regulating immune memory. CD40 signaling is essential for T cell-dependent humoral responses and targeting vaccine antigen to CD40 expressing APC seems therefore an attractive option to promote…

CHARACTERIZING ANTIBODY RESPONSES IN ART-TREATED INDIVIDUALS

Although suppression of HIV has become possible through antiretroviral therapy (ART), ART-treated individuals must maintain therapy to avoid rebound from a viral reservoir. Strategies to limit or clear this reservoir are urgently needed. Research has shown that individuals infected for longer prior to receiving ART harbor greater reservoir diversity, but may also have higher anti-HIV antibody…

MUCOSAL T AND B CELL RESPONSES INDUCED BY ALVAC-HIV/AIDSVAX B/E LATE BOOST STRATEGIES

The majority of HIV-1 infections occur across mucosal surfaces, hence mucosal immune responses including CTL, T-helper cells and IgA-secreting plasmablasts (PB) are part of the initial defense against infection. RV144 is still the only vaccine trial that demonstrated modest efficacy; however, mucosal responses were not characterized. Here we assess mucosal immune responses elicited after the…